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DR3 (TRAMP, LARD, WSL-1, TNFRSF25) is a death-
domain-containing tumor necrosis factor (TNF)-
family receptor primarily expressed on T cells. TL1A,
the TNF-family ligand for DR3, can costimulate T
cells, but the physiological function of TL1A-DR3 in-
teractions in immune responses is not known. Using
DR3-deficient mice, we identified DR3 as the recep-
tor responsible for TL1A-induced T cell costimulation
and dendritic cells as the likely source for TL1A dur-
ing T cell activation. Despite its role in costimulation,
DR3 was not required for in vivo T cell priming, for
polarization into T helper 1 (Th1), Th2, or Th17 effec-
tor cell subtypes, or for effective control of infection
with Toxoplasma gondii. Instead, DR3 expression
was required on T cells for immunopathology, local
T cell accumulation, and cytokine production in
Experimental Autoimmune Encephalomyelitis (EAE)
and allergic lung inflammation, disease models that
depend on distinct effector T cell subsets. DR3 could
be an attractive therapeutic target for T cell-medi-
ated autoimmune and allergic diseases.
INTRODUCTION
Interactions between tumor necrosis factor (TNF)-family ligands
and receptors play an important role in shaping specific features
of T cell responses. A subfamily of TNF receptors, including
CD30, TNFR2, OX40, CD27, GITR, HVEM, and 4-1BB, is ex-
pressed on T cells. These receptors mediate distinct aspects
of costimulation in specific T cell subsets (Croft, 2003; Watts,
2005). Death Receptor 3 (DR3), also known as TNFRSF25,
TRAMP, LARD, or WSL-1, is a death-domain-containing TNF-
family receptor that, like its closest paralog TNFR1, binds the
adaptor molecule TRADD through its cytoplasmic death domain.
TRADD recruitment endows DR3 with dual-signaling capability
to activate NFkB and MAP-kinase signaling or alternativelytrigger caspase activation and programmed cell death (Chin-
naiyan et al., 1996; Screaton et al., 1997; Wen et al., 2003). How-
ever, unlike TNFR1, which is widely expressed, DR3 has been
reported to be expressed primarily by T lymphocytes (Screaton
et al., 1997; Su et al., 2004). The ligand for DR3 was identified
in 2002 as the TNF-family member TL1A (Migone et al., 2002).
When added to certain tumor cell lines, TL1A can induce apopto-
sis after addition of cycloheximide. However, in primary T cells,
TL1A has been reported to enhance proliferation and production
of interleukin-2 (IL-2) and interferon-g (IFN-g) induced by T cell
receptor (TCR) crosslinking (Migone et al., 2002; Papadakis
et al., 2004). TL1Awas originally reported to be expressed exclu-
sively in endothelial cells (Migone et al., 2002), but more recently
TL1A has been found to be highly expressed in dendritic cells
(DCs) after in vitro activation and in Crohn’s disease, rheumatoid
arthritis, and mouse models of inflammatory bowel disease, (Ba-
mias et al., 2003; Bamias et al., 2006; Cassatella et al., 2007). Ge-
netic variants in TL1A and DR3 have also been associated with
Crohn’s disease and rheumatoid arthritis, respectively (Osawa
et al., 2004; Yamazaki et al., 2005).
Although exogenous TL1A is a T cell costimulator, the role of
DR3 in peripheral T cell responses is not known. DR3-deficient
mice exhibit a mild defect in thymic negative selection, but pe-
ripheral T cell numbers and subsets are normal (Wang et al.,
2001). Spleens from DR3-deficient mice also have normal
numbers of myeloid DCs (CD11b+CD11chiB220-PDCA), plas-
macytoid DCs (CD11bCD11cintB220+PDCA+), macrophages,
monocytes, and granulocytes (F.M., E.C.Y.W., and R.M.S, un-
published observations). Understanding the physiological and
pathophysiological roles of DR3 in immune responses is impor-
tant for predicting the therapeutic and possibly deleterious con-
sequences of blocking TL1A-DR3 interactions. Here, we have
analyzed peripheral T cell responses in mice rendered deficient
in DR3 through gene targeting. Exogenous TL1A functioned as
a costimulator of T cell proliferation and cytokine production in
wild-type (WT) T cells but not in DR3-deficient T cells, confirming
the role of DR3 as an authentic and nonredundant costimulatory
receptor for TL1A. However, DR3-deficient T cells only displayed
defects in proliferation and cytokine production when activated
in the presence of DCs, showing that DCs, rather than T cells,Immunity 29, 79–89, July 18, 2008 ª2008 Elsevier Inc. 79
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lation. Despite DR30s role in costimulation, DR3-TL1A interac-
tions were not required for polarization of naive CD4+ T cells
into T helper 1 (Th1), Th2, or Th17 effector cell subtypes, and T
cell priming and systemic production of effector cytokines
were normal in response to a number of model antigens and
pathogens. Strikingly, however, immunopathology was dramat-
ically reduced in the target organs of two different models of T
cell-mediated inflammatory disease. These studies reveal a spe-
cific, nonredundant function for DR3 in controlling the function of
effector CD4+ T cells in the target organs of autoimmune and
inflammatory diseases.
RESULTS
TL1A Costimulates CD4+ T Cells through DR3
By searching through the SymAtlas gene-expression database,
we confirmed that DR3 is primarily expressed on T cells in
both mouse and man (Figure S1, available online). Exogenous
TL1A can costimulate human and mouse T cells, but whether
DR3 is the sole costimulatory receptor for TL1A andwhat role en-
dogenously produced TL1A plays in T cell activation are not
known. To investigate, we purified CD4+ T cells from spleens
and lymph nodes of WT or age- and sex-matched DR3-deficient
(Tnfrsf25/) mice (Wang et al., 2001) on a C57BL/6 background
Figure 1. TL1A Costimulates Proliferation
and Cytokine Production in CD4+ T Cells
through DR3
(A) Purified CD4+ T cells fromWTC57BL/6 or DR3-
deficient (Tnfrsf25/) mice were activated with
anti-CD3 or anti-CD3 and anti-CD28 in the pres-
ence or absence of 10 ng/ml of mouse rTL1A for
3 days. 3H-thymidine was added to the culture, in-
cubated overnight, and analyzed for thymidine in-
corporation. Error bars represent SEM of triplicate
samples.
(B) Purified T cells from C57BL/6 were cultured as
above but also in the presence of 10 mg/ml of IL-
2Ra (CD25) antibody or isotype control for 3
days (left panel). Purified T cells from Il2/ or
Il2+/+ mice were cultured as above, in the absence
or presence of 10 U/ml of IL-2 for 3 days (middle
and right panels). Error bars represent SEM of
triplicate samples.
(C) Supernatants from CD4+ T cells activated and
cultured as in (A) were harvested at the indicated
time points, and the indicated cytokines were
measured with cytokine bead arrays. n.d. indi-
cates ‘‘below limit of detection’’ (4 pg/ml). A repre-
sentative of three experiments for each panel is
shown.
and activated them through the TCR in
the presence or absence of recombinant
murine TL1A. Costimulation by other
TNF-family members has been shown
to be maximal when CD28-mediated
costimulation is blocked (Croft, 2003). At
concentrations of 10 ng/ml or above,
TL1A increased T cell proliferation most
dramatically in the absence of CD28-mediated costimulation
(Figure 1A). When CD28-mediated costimulation was present,
TL1A costimulated proliferation only at suboptimal doses of
anti-CD3 (Figure 1A). The increased thymidine incorporation
was due to increased cell division and not to enhanced survival,
given that we observed increased CFSE dilution and no signifi-
cant changes in cellular viability induced by TL1A (data not
shown). Importantly, DR3-deficient cells were unresponsive
to TL1A, indicating that DR3 is the major receptor that mediates
costimulation by TL1A (Figure 1A). However, stimulation of DR3
through endogenous T cell-derived TL1A was apparently dis-
pensable for T cell proliferation, because there were no deficits
in proliferation in cultures of purified Tnfrsf25/ T cells
(Figure 1A). TL1A costimulation was largely dependent on in-
creased IL-2 production, given that TL1A-induced proliferation
was greatly reduced in IL-2-deficient T cells or those towhich an-
tagonistic IL-2Ra (aCD25) antibody had been added (Figure 1B).
To investigate the spectrum of cytokines that can be costimu-
lated by TL1A and the dependence of cytokine production on
DR3, we measured IL-2, IFN-g, and IL-4 production in WT or
Tnfrsf25/ T cells activated in the presence or absence of
recombinant TL1A. TL1A increased IL-2, IFN-g, and IL-4 produc-
tion by WT but not by Tnfrsf25/ T cells, with IL-4 most promi-
nently induced by TL1A in the presence of CD28 costimulation
(Figure 1C). DR3-deficient T cells were unresponsive to TL1A80 Immunity 29, 79–89, July 18, 2008 ª2008 Elsevier Inc.
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T cells. Thus, as with proliferative responses, DR3 expression
is required for TL1A-induced costimulation, but endogenously
produced TL1A is not necessary for cytokine production by
activated T cells under these conditions.
TL1A has been reported to costimulate memory T cells but not
naive T cells (Bamias et al., 2006). To address this issue, we pu-
rified CD62Lhi CD44lo naive CD4+ T cells from WT and DR3-
deficient mice and activated them with or without exogenous
TL1A. TL1A mildly enhanced proliferation with or without CD28
costimulation and strongly increased IL-2 (8-fold) and IFN-g
(10-fold) production in a DR3-dependent manner (Figures S2A
and S2B), showing that DR3 can function in naive T cells by
increasing cytokine production. Percentages of phenotype
CD44hi CD4+ memory T cells were also identical in age-matched
Tnfrsf25/ and control mice (Figure S2C), indicating that TL1A
costimulation of total CD4+ T cells is unlikely to be due to differ-
ences in the percentages of memory and naive T cells.
DCs Produce TL1A in Response to TLR and FcgR Stimuli
The lack of proliferation or cytokine-production defects in puri-
fied DR3-deficient T cells suggested that other cell types might
be the physiological source of TL1A. TL1A has been reported
to be produced by human DCs and monocytes after a variety
of stimuli, and DCs would be a source of TL1A produced at the
appropriate time and place for T cell costimulation. To test this
hypothesis, we measured upregulation of TL1A gene expression
by Reverse Transcriptase Quantitative PCR (RT-qPCR) in puri-
Figure 2. Differential Induction of TL1AExpression in DCs
and T Cells
(A) Bone-marrow-derived DCs or CD11c+ DCs from WT C57BL/6
mice were cultured and stimulated for the indicated time with or
without 100 ng/ml of LPS, 20 mg/ml of SEA, or 10 mg/ml of
STAg. RNA was prepared from each sample and used in re-
verse-transcriptase quantitative PCR (RT-qPCR).
(B) Bone-marrow-derived DCs fromWT C57BL/6 mice or the indi-
cated mutant mice were cultured and stimulated in the presence
or absence of 100 ng/ml LPS for 3 hr. RNA was prepared from
each sample and used in RT-qPCR.
(C) Bone-marrow-derived DCs from WT C57BL/6 mice were cul-
tured and stimulated for the indicated times with or without
100 ng/ml LPS or Ig cross-linking, and RNA was prepared from
each sample and used in RT-qPCR.
(D) Purified T cells fromWTC57BL/6 or Tnfrsf25/mice were cul-
tured and stimulated with 5 mg/ml of anti-CD3 and anti-CD28 for
the indicated time. RNA was prepared from each sample and
used in RT-qPCR.
Results indicate the amount of TL1A mRNA calculated relative to
the untreated cells of each population (A–C) or relative to unstimu-
lated T cells of each genotype (D). TL1A basal mRNA levels in T
cells were approximately 50-fold lower than those in DCs. Error
bars represent SEM of triplicate samples. A representative of
two (A, B and C), one (D right panel), or three (D, left panel) exper-
iments is shown.
fied splenic CD11c+ DCs and bone-marrow-derived
DCs stimulated with a variety of agents. LPS and Sol-
uble Tachyzoite Antigen (STAg) from Toxoplasma gon-
dii acts through Toll-like receptors (TLRs) that can in-
duce expression of other TNF-family members. LPS
induced TL1A in bone-marrow-derived DCs, and STAg-induced
TL1A in splenic DCs that express TLR11 required for STAg re-
sponsiveness (Yarovinsky et al., 2005). Expression peaked at
up to 100-fold above baseline at 3 hr and rapidly declined after
that (Figure 2A). Interestingly, Schistosoma Egg Antigen (SEA)
from Schistosoma mansoni, which triggers alternative activation
of DCs to program T cells for Th2 cell differentiation, did not ap-
preciably induce TL1A mRNA (Figure 2A, left panel). Stimulation
of DCs deficient in TLR-signaling components showed that LPS
induction of TL1A wasmediated by TLR4 in amanner dependent
on MyD88 and TIRAP (Figure 2B). Immune complexes acting
through low-affinity Fc receptors have recently been shown to
be a potent stimulus for TL1A production (Cassatella et al.,
2007; Prehn et al., 2007). Stimulation of murine DCs with plate-
bound cross-linked mouse Ig (IC) also stimulated TL1A gene
expression, comparable to LPS (Figure 2C). Thus, like other
TNF-family members, TL1A can be rapidly induced in DCs
through TLR and immune complexes.
To test whether T cells could serve as an autocrine source
of TL1A, purified T cells were stimulated through the TCR, and
TL1A mRNA expression was measured by RT-qPCR. TL1A
mRNA was upregulated after TCR stimulation, but with delayed
kinetics as compared to that of DCs. Interestingly, TL1A upregu-
lation was specifically dependent on DR3 expression, given that
DR3-deficient T cells showed dramatically reduced TL1A induc-
tion but normal upregulation of IL-2 mRNA after activation
(Figure 2D). Taken together, these data show that T cells can
produce TL1A that acts in an autocrine manner to sustain itsImmunity 29, 79–89, July 18, 2008 ª2008 Elsevier Inc. 81
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Proliferation and Altered Cytokine Produc-
tion when Cultured in the Presence of DCs
(A) Bone-marrow-derived DCs were cultured with
naive OT-II or Tnfrsf25/ OT-II CD4+ T cells in
the presence of indicated Ova-peptide concentra-
tion and in the absence (left panel) or presence
(right panel) of CTLA4-Ig for 3 days. 3H-thymidine
was added to the culture, incubated overnight,
and analyzed for thymidine incorporation. (B)
Supernatants from the above cultures were
harvested after 72 hr and tested for cytokine pro-
duction. n.d. indicates ‘‘below limit of detection’’
(4 pg/ml). A representative of three experiments
for each panel is shown.own expression but that T cell-derived TL1Amight not be neces-
sary for proliferation or cytokine production by isolated T cells.
DR3 isNot Required for Th1, Th2, or Th17Differentiation
of Naive T Cells
To study the role of TL1A-DR3 interactions in a more physiolog-
ical model of T cell activation, we backcrossed DR3-deficient
mice to the Ovalbumin (Ova)-specific TCR transgenic line OT-II
and cultured naive T cells from Tnfrsf25/ OT-II and OT-II con-
trol mice with Ova peptide and WT bone-marrow-derived DCs.
Under these conditions, proliferation of Tnfrsf25/ OT-II cells
was diminished, especially at low concentrations of Ova
(Figure 3A), whether costimulation through B7 was blocked by
the addition of CTLA4-Ig or not. The cytokine profile of T cells
stimulatedwith Ova peptide andDCs is characteristically depen-
dent on the dose of antigen, with higher doses favoring IFN-g
production and lower doses favoring IL-4 production (Tao
et al., 1997). Tnfrsf25/ OT-II cells produced less IL-2 at lower
doses of Ova and less IL-4 at all doses of Ova tested. By con-
trast, Tnfrsf25/ OT-II cells produced marginally higher
amounts of IFN-g compared with those of controls at all doses
tested (Figure 3B). These data suggest that during cognate inter-
actions between antigen-specific T cells and DCs, TL1A-DR3 in-
teractions function to costimulate T cell proliferation and produc-
tion of IL-2, IL-4, but not IFN-g.
These alterations in cytokine production and proliferation sug-
gest that DR3 may influence T cell polarization. To test this, we
activated naive CD4+ T cells from Tnfrsf25/ or control mice
in the presence of DCs, under conditions optimal for differentia-
tion of Th1, Th2, or Th17 effector T cells or under neutral condi-
tions, and we measured cytokine production after restimulation
(Figure 4). In the absence of exogenous polarizing stimuli, both
WT and Tnfrsf25/ T cells exhibited mild skewing toward
a Th1-IFN-g-secreting profile expected on the C57BL/6 back-
ground. In addition, Tnfrsf25/ T cells could be polarized nor-
mally toward IL-4-, IFN-g-, or IL-17-producing cells (Figure 4A).
We then set up cultures of Tnfrsf25/ OT-II and control OT-II
T cells stimulated with DCs and Ova and polarized them with cy-82 Immunity 29, 79–89, July 18, 2008 ª2008 Elsevier Inc.tokines or with STAg, which induces TL1A production. These
conditions also resulted in normal Th1 cell skewing by antigen-
specific Tnfrsf25/ T cells (Figure 4B). Induction of the tran-
scription factors T-bet, GATA-3, or RORg by appropriate differ-
entiation stimuli was also unaffected in purified Tnfrsf25/
T cells (data not shown). Thus, TL1A-DR3 interactions appear
to be dispensable for the in vitro differentiation of naive T cells
into Th1, Th2, or Th17 effector cell subtypes.
DR3 is Required for Immunopathology in Experimental
Autoimmune Encephalomyelitis
To determine the role of DR3 in T cell differentiation and effector
function in the intact immune system, we studied disease
models dependent on distinct T cell subsets in Tnfrsf25/
mice. We first studied Experimental Autoimmune Encephalomy-
elitis (EAE), an autoimmune-disease model dependent on Th17
and Th1 cell subsets. In four separate experiments, Tnfrsf25/
mice exhibited dramatically reduced paralysis, measured by
clinical scores (Figure 5A). Despite profound resistance to EAE,
T cells from draining lymph nodes of myelin oligodendrocyte gly-
coprotein (MOG)-primed Tnfrsf25/ mice proliferated normally
in response to most doses of MOG (Figure 5B). In accordance
with the clinical scores, the total yield and percentage of CD4+
T cells was markedly reduced in spinal-cord homogenates
from pooled Tnfrsf25/ mice compared to that of controls
(Figure 5C). Within the T cell gate, the percentage of IFN-g-pro-
ducing cells was reduced by 50% in T cells from the spinal cords
of Tnfrsf25/mice (Figure 5C). The percentage of IL-17-produc-
ing cells was normal in Tnfrsf25/ mice within this gate, but
overall, it was reduced due to the decreased percentage of
CD4+ T cells in the spinal cord. To examine the absolute amounts
of these cytokines in the inflamed spinal cord, mRNA for IL-17
and IFN-g was measured by RT-qPCR in spinal-cord homoge-
nates. Both cytokines were reduced in spinal-cord preparations
from MOG-primed Tnfrsf25/ mice when normalized to the
housekeeping gene b2-microglobulin, with IFN-g the most af-
fected. However, when normalized to the expression of the
T cell-specific gene CD3d, IL-17 and IFN-g mRNA expression
Immunity
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DR3 is critical for immunopathology in EAE and appears to
act principally by controlling the accumulation of T cells in the
spinal cord.
To investigate whether DR3 expression on T cells is responsi-
ble for mediating these effects, we performed transfer experi-
ments in which Tnfrsf25/ or WT CD4+ T cells were transferred
into TCRa-deficient mice (Figure 5E). The mice were then immu-
nized with MOG. Mice receiving DR3-deficient T cells exhibited
dramatically reduced paralysis compared to that of mice receiv-
ingWT T cells. As with EAE in Tnfrsf25/mice, there were fewer
CD4+ T cells in the spinal-cord homogenates of mice induced to
develop EAE that received DR3-deficient T cells, with the per-
centages of CD4+ T cells correlating closely with disease score
in each mouse (data not shown). Thus, DR3 expression is re-
quired on T cells for immunopathology in this mouse model
of autoimmune demyelinating disease.
DR3 Is Required for Th2 Cell-Mediated Lung
Inflammation but Not for Systemic Th2 Cell Responses
We next investigated a Th2 cell-dependent model of lung inflam-
mation in which mice are primed systemically with Ova and Alum
Figure 4. DR3 is Not Required for Th1, Th2,
or Th17 Differentiation of Naive T Cells
(A) T-depleted APCs were cultured with C57BL/6
or Tnfrsf25/ purified naive CD4+ T cells in the
presence of soluble anti-CD3 (1 mg/ml) and anti-
CD28 (3 mg/ml) under Th0, Th1, Th2, or Th17 cell
polarization conditions for 4 days. Cells were
then restimulated with PMA and Ionomycin for
5–6 hr, stained for intracellular cytokines, and
analyzed by flow cytometry.
(B) Sorted CD11c+ DCswere cultured with OT-II or
Tnfrsf25/OT-II purified naive CD4+ T cells in the
presence of 1 mM Ova peptide under Th0, Th1, or
Th2 cell polarization conditions or in the presence
of STAg for 6 days. Cells were then restimulated
with anti-CD3 and anti-CD28 for 5–6 hr, stained
for intracellular cytokines, and analyzed by flow
cytometry.
A representative of two (A) and three (B) experi-
ments is shown.
and then locally challenged with Ova
(Gavett et al., 1994). In three independent
experiments, histological analysis
showed that the airways in Tnfrsf25/
mice lungs had less inflammation, includ-
ing mucin production and peribronchial
inflammation (Figure 6A). Standardized
histopathology scores and cell counts in
bronchoalveolar lavage (BAL) were re-
duced in Ova-sensitized and -challenged
Tnfrsf25/ mice compared with those in
WT mice sensitized and challenged in
parallel with Ova (Figure 6B). The per-
centages of CD3+ and CD4+ T cells, in-
variant Va14+ natural killer T (NKT) cells, and eosinophils were
all significantly reduced in lung cell preparations from Ova-sen-
sitized and -challenged Tnfrsf25/ mice in comparison to con-
trols (Figure 6C). Immunohistochemical localization of CD3+ cells
in lung tissue from Ova-sensitized DR3-deficient mice revealed
fewer interstitial and peribronchial T cells and increased perivas-
cular localization as compared to controls. Similar increases in
perivascular infiltrates were observed for macrophages
(Figure S3). Expression of mRNA for IL-5 and IL-13, which are
critical for Th2-mediated lung pathology, was markedly reduced
in Tnfrsf25/ Ova-sensitized lungs, whereas IL-10 and IFN-g
were produced equally (Figure 6D). By contrast, when
Tnfrsf25/-spleen cells from these mice were restimulated
with Ova, there was normal production of IL-5 and IL-13, indicat-
ing that systemic priming of Ova-specific Th2 T cells was inde-
pendent of DR3 (Figure 6E). In addition, Tnfrsf25/ splenocytes
proliferated normally in response to Ova (data not shown). Sys-
temic Th2 cell function, assessed by the production of Ova-spe-
cific IgG1 and Ova-specific IgE after Ova priming, was also
normal in Tnfrsf25/ mice (Figure 6F). Thus, in this model of
Th2-mediated lung inflammation, DR3 expression is required
for accumulation of Th2 effector cells at the site of inflammation
but not for systemic differentiation of Th2 cells. DecreasedImmunity 29, 79–89, July 18, 2008 ª2008 Elsevier Inc. 83
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phils and invariant NKT (iNKT) cells to the site of inflammation, as
was observed in the Tnfrsf25/ lung.
To investigate in more detail the role of DR3 in the trafficking
and local proliferation of antigen-specific T cells and to deter-
mine whether the requirement for DR3 is T cell intrinsic in this dis-
ease model, we performed transfer experiments in which
Tnfrsf25/ OT-II Ova-specific T cells and OT-II controls were
activated in vitro under Th2 cell differentiation conditions and
then transferred into naive congenic host mice. Recipients
were then given a respiratory challenge with Ova, and responses
were analyzed after 1 or 2 days. In this system, when antigen was
only delivered locally to the lung, we saw a significant defect in
accumulation and proliferation of primed Ova-specific T cells
in the lung, with an even more profound defect in the recovery
and proliferation of Tnfrsf25/OT-II T cells in the draining medi-
astinal lymph nodes (Figures 7A and 7B). Inflammatory cells in
Figure 5. Tnfrsf25/ Mice are Resistant to
EAE and Have Reduced Numbers of T Cells
in the Spinal Cord
(A) EAE was induced in Tnfrsf25/ mice and
C57BL/6 control mice as described in the Experi-
mental Procedures, and clinical scores were mea-
sured daily. One of four experimental trials is
shown, with a minimum of five mice in each group.
(B) Draining lymph nodes from the site of MOG in-
jection were harvested, and cells were restimu-
lated with the indicated amounts of MOG peptide.
T cell proliferation was assessed by 3H-thymidine
incorporation after 3 days.
(C) T cell yield and function from spinal-cord prep-
arations. Spinal-cord homogenates were pre-
pared from mice at day 28 of EAE. The yield of
CD4+ T cells obtained from spinal-cord prepara-
tions of WT mice was 2.26 3 105, versus 1.6 3
105 CD4+ T cells from spinal-cord preparations
of Tnfrsf25/ mice. The average clinical score of
the mice used in this experiment was 2.75 in the
WT group and 1 in the Tnfrsf25/ group. Cells
harvested from spinal cords were restimulated
for 4 hr with anti-CD3 and anti-CD28 and analyzed
by flow cytometry for T cell-surface markers, and
gated CD45+CD4+ cells were analyzed for intra-
cellular cytokine production.
(D) mRNA from spinal cords or spleens of the
same groups of mice shown in (C) was analyzed
by RT-qPCR for IL-17 and IFN-g mRNA. Results
are normalized to b2 m or CD3d. Error bars repre-
sent SEM of triplicate samples.
(E) EAE was induced in TCRa-deficient mice re-
constituted with Tnfrsf25/ or WT CD4+ T cells
as described in the Experimental Procedures,
and clinical scores were measured daily.
Data is representative of four (A), two (B), and four
(C) experiments.
the BAL were correspondingly reduced
in recipients of Tnfrsf25/ OT-II T cells
(Figure 7C). These experiments clearly
show that DR3 expression on T cells is
necessary for proper local responses of
primed T cells to cognate antigen. It is
possible that this phenotype could stem from a generalized re-
quirement for DR3 to be expressed on T cells in order for them
to acquire the ability to migrate to extralymphatic tissues. How-
ever, when naive DR3-deficient T cells were transferred into con-
genic hosts and Ova was delivered systemically with LPS used
as an adjuvant, T cells migrated normally to lung, liver, and intes-
tinal sites as efficiently asWTOT-II T cells (Figure S4). Thus, DR3
expression on T cells appears to be critical for tissue homing and
proliferation only for locally restimulated T cells.
The defective autoimmune and inflammatory responses in
Tnfrsf25/mice suggest that cellular responses to infectious or-
ganismsmight also be dependent on DR3. We have investigated
this by studying the role of DR3 in immune responses to Toxo-
plasma gondii, a parasite for which IFN-g-secreting Th1 cells
are critical for host defense and survival of infected mice. After
infection with T. gondii, all Tnfrsf25/mice survived acute infec-
tion. Spleen cells isolated from infected Tnfrsf25/ mice at84 Immunity 29, 79–89, July 18, 2008 ª2008 Elsevier Inc.
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-Mediated Lung Inflammation
Mice were sensitized with Alum + PBS (control) or
Alum + Ova. Mice were then challenged with PBS
(control) or Ova.
(A) Examples of PAS-stained histology are shown,
with airways (aw) and infiltrating cells (arrowheads)
shown.
(B) Histopathology of the lungs was scored (left
panel), and cells in the BAL were counted (right
panel).
(C) Cells were extracted from the lungs and ana-
lyzed by flow cytometry for the percentage of the
indicated subsets out of the total live cell popula-
tion. Siglec F was used to measure eosinophils
as previously described (Norris et al., 2007). invari-
ant ‘type-I’ NKT (iNKT) cells were enumerated
with CD1d-PBS57 tetramer, which identifies
Va14Ja18+ T cells responsive to alpha-gal-cer
sphingolipid.
(D) RNA was prepared from lungs and used in RT-
qPCR. Results indicate the amount of cytokine
mRNA calculated relative to the lungs of control
mice treated with PBS. p values are for unpaired
t tests on mRNA levels of the indicated cytokines
between Tnfrsf25/ and control mice induced
with Ova.
(E) Splenocytes were cultured in the presence of
50 mg/ml of Ova protein or media control for
3 days. Supernatants were analyzed for cytokine
production by cytometric bead array.
(F) Serum was tested for Ova-specific IgE and
Ova-specific IgG1 concentration by ELISA. p
values obtained by comparison of groups with
an unpaired two-tailed t test are shown where sig-
nificant; n.s. indicates ‘‘not significant.’’
A representative of three (A and B), a representa-
tive of two (C, E, F), and a pool of two (D) experi-
ments are shown.seven weeks after infection produced comparable amounts of
TNF-a, IFN-g, and IL-10 in response to STAg as compared to
controls (Figure S5A). Immune responses to toxoplasma infec-
tion were also intact, as indicated by similar counts of toxo-
plasma cysts in the brains of WT and Tnfrsf25/ animals
(Figure S5B). Infiltrating CD3+ T cells were present in similar
amounts in histological sections of the brains of WT and
Tnfrsf25/ mice (data not shown). In addition, Toxoplasma-in-
fected Tnfrsf25/mice survived at rates similar to, if not greater
than, infected WT mice at later stages of infection (Figure S5C).
These data indicate that, at least in the case of T. gondii, priming
and maintenance of effector T cells responsible for controlling
acute and chronic infections are not dependent on DR3.
DISCUSSION
TNF receptors expressed on T cells have been found to play dis-
tinct roles in costimulation, survival after activation, and forma-
tion of T cell memory (Croft, 2003; Watts, 2005). Here, we havefound that TL1A-DR3 interactions can enhance T cell prolifera-
tion and cytokine production but are largely dispensable for dif-
ferentiation into diverse effector T cell subsets in vitro and in vivo.
Our findings provide strong evidence that DR3 is required for ef-
fective T cell immune responses in the target organs of T cell-me-
diated autoimmune and inflammatory diseases, whereas DR3 is
not required for an effective response to the parasite T. gondii.
Our results suggest that the cellular source of TL1A influences
the biological outcome of DR3 engagement on T cells. DCs are
the most likely source of TL1A for T cells at the time of antigen
presentation, and DR3 is required for costimulation by DC-de-
rived TL1A. TL1A is rapidly upregulated in DCs through TLR or
FcR and then rapidly returns to baseline expression. T cells are
also able to upregulate TL1A after stimulation through the TCR,
but mRNA upregulation is slower and is sustained for at least
48 hr after activation. TL1A produced by T cells can bind to
DR3 and enhance TL1A production through an autocrine feed-
back loop. This contrasts with OX40L and FasL, which are hyper-
expressed by T cells in the absence of their cognate receptorsImmunity 29, 79–89, July 18, 2008 ª2008 Elsevier Inc. 85
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the plasma membrane by metalloproteases in endothelial and
dendritic cells but not in T cells (Kim and Zhang, 2005; F.M., un-
published observations). TL1A produced by T cells in an auto-
crine manner may sustain costimulation, although we did not
find any functional consequences of DR3 deficiency in isolated
T cells in terms of proliferation, cytokine production, or differen-
tiation. Even in the presence of DCs and TL1A-inducing stimuli,
DR3 was not required for T cell polarization of Th1, Th2, or
Th17 cell subsets in vitro or in vivo. However, these conclusions
must be tempered by the fact that we have only examined TL1A
expression in mouse T cells at the RNA level and the possibility
that there might be very little TL1A produced under these condi-
tions and even less by Tnfrsf25/ T cells.
Despite the relatively modest role of DR3 in T cell activation in
vitro, our data on T cell-dependent animal-disease models es-
tablish for the first time an essential role of DR3 in T cells within
target tissues during autoimmune and allergic inflammation. Im-
munopathology and clinical disease were decreased both in a
Th2-driven model of Ova-induced lung inflammation and
Figure 7. T Cell-Intrinsic Requirement for DR3 in Allergic
Lung Hypersensitivity
23 106 CFSE-labeled T cells from Th2-polarized Tnfrsf25/OT-II
or OT-II T cells were transferred into CD45.1 congenic recipient
mice, and the recipient mice were challenged with i.t.-adminis-
tered Ova once 24 hr later (24 hr condition) or with i.t.-adminis-
tered Ova 24 hr after transfer and i.n.-administered Ova 48 hr after
transfer (48 hr condition). All mice were killed 72 hr after cell trans-
fer. Four recipients per experimental group were used, and two
mice receiving WT and Tnfrsf25/ T cells were kept as unchal-
lenged controls (‘‘none’’).
(A) Average yield of CD45.2+ T cells, per lung or in pooled medias-
tinal lymph nodes, from each group.
(B) Representative CFSE profiles of CD45.2 donor cells from re-
cipients of WT and Tnfrsf25/ donor T cells challenged with
Ova for 48 hr.
(C) The average ± SEM Eosinophil and Neutrophil cell counts in
BAL from mice receiving WT or Tnfrsf25/ T cells challenged
with Ova for the indicated period of time. A representative of two
experiments is shown.
in EAE, which depends on Th1 and Th17 cells. In
both models, the accumulation of T cells in the target
tissue and the production of effector cytokines spe-
cific for that model were decreased. After submission
of this manuscript, two other independent studies us-
ing TL1A-deficient mice and DR3-dominant-negative
transgenic mice implicated TL1A-DR3 interactions in
Th17 cell responses (Pappu et al., 2008) and in allergic
lung inflammation (Fang et al., 2008), respectively. Our
results show that both disease models require DR3
irrespective of the specific Th cell subtype involved.
Remarkably, we found that induction of systemic im-
mune responses to Ova and MOG were, unlike local
T cell responses, independent of DR3, as measured
by peripheral T cell proliferation, cytokine production,
or T cell help for antibody responses. In both lung hy-
persensitivity and EAE, the requirement for DR3 was
T cell intrinsic, as indicated by the transfer experiments in which
DR3 was deficient only on T cells.
The requirement for DR3 in T cell-mediated inflammatory dis-
ease as seen in these animal models could be due to the induc-
tion of TL1A in the target organ or draining lymph node during
secondary T cell responses. TL1A produced in the area of inflam-
mation might enhance survival, migration, or proliferation of
T cells in target tissues throughDR3 signaling. Enhanced survival
due to TL1A seems unlikely, given that we have not observed an
increase in apoptotic cells in preparations of lung or spinal-cord
homogenate from Tnfrsf25/ mice during lung hypersensitivity
or EAE (F.M. and R.M.S., unpublished observations). DR3 could
also function to enhance effector-cytokine production by T cells
at the site of inflammation, although defects in production of ef-
fector cytokines on a per-cell basis do not appear to explain the
dramatic effects of DR3 deficiency on the severity of EAE. Al-
though fewer cells were detected in the lungs and spinal cords
of mice with inflammation in these organs, this does not stem
from a requirement for DR3 in extralymphatic trafficking of acti-
vated T cells, given the normal ability of T cells to home to the86 Immunity 29, 79–89, July 18, 2008 ª2008 Elsevier Inc.
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reduction in proliferation and expansion of DR3-deficient Ova-
specific T cells in the mediastinal lymph nodes and lungs of
mice after pulmonary challenge with Ova suggests that a critical
function of DR3 stimulation is to costimulate antigen-induced
expansion of primed T cells in the target organ of T cell-mediated
autoimmune and inflammatory diseases. By contrast, given that
this model does not require secondary re-expansion of T cells,
DR3 might not be required for the acute Th1 cell response to
T. gondii. DR3 might not be required for control of brain cysts
in the chronic phase of T. gondii infection, given that control of
brain cysts has been shown to be more dependent on CD8+
than on CD4+ T cells (Parker et al., 1991; Scorza et al., 2003).
Thus far, we have not found any defects in primary or secondary
CD8+ T cell responses in Tnfrsf25/ mice (F.M. and R.M.S., un-
published observations). DR3’s role in T cell immunity to other
infectious agents will need to be further tested if we are to
know how applicable our findings are to other infections.
Other TNF-family members that costimulate T cells have been
reported to contribute to EAE and allergic inflammation, but
blockade of most other TNF-family receptors generally affects
systemic immune responses aswell as target-organ-specific pa-
thology. For example, OX40 has been shown to be important in
the generation of a systemic, as well as a local, Th2 cell response
in asthma (Arestides et al., 2002; Salek-Ardakani et al., 2003).
A blocking antibody against CD70 (ligand for the CD27 costimu-
latory receptor on T cells) ameliorated EAE but also depressed
systemic immune responses (Nakajima et al., 2000). Antibody
blockade of OX40L was reported to decrease influx of T cells
into the brain in EAE (Nohara et al., 2001). Interestingly, like
TL1A, OX40L expression is induced in endothelial cells by pro-
inflammatory stimuli.
These results make DR3 a relatively unique TNF-family recep-
tor in terms of its role in promoting T cell accumulation and pa-
thology in autoimmune- and inflammatory-disease models
depending on a diverse set of cytokines and Th cell subsets.
The role of DR3 in promoting T cell-mediated immunopathology
strikingly parallels the role of its paralog, TNFR1, as an amplifier
of innate immune responses. The signaling pathways by which
DR3 accomplishes this, as well as the molecular mechanisms
underlying this specific function of DR3, will be an interesting
topic for further study. Because primary T cell responses and
host defense are relatively preserved in Tnfrsf25/mice, block-
ing the action of TL1A might be less generally immunosuppres-
sive than blocking TNF or non-TNF cytokines. This makes block-
ing TL1A-DR3 interactions a promising strategy for therapy in a
wide variety of T cell-dependent autoimmune diseases.
EXPERIMENTAL PROCEDURES
Reagents and Mice
LPS from E. Coli was obtained from Sigma. STAg was prepared from soni-
cated Toxoplasma gondii tachyzoites, and SEA was prepared from Schisto-
soma mansoni eggs as previously described (Grunvald et al., 1996). C57BL/6
mice were obtained from Jackson Laboratories. DR3-deficient mice, gener-
ated as previously described (Wang et al., 2001), were backcrossed to the
C57BL/6 background for at least eight generations. DR3-deficient OT-II
micewere generated by the crossing of DR3-deficientmice toOT-II TCR trans-
genic mice (Taconic). Il-2/mice were a generous gift from Pushpa Pandiyan,
NIAID. All antibodies were purchased from BD pharmingen unless indicatedotherwise. CD1d/PBS57 tetramers that recognize Va14 iNKT cells were pre-
pared by the National Institutes of Health (NIH) tetramer core facility.
B6.CD45.1 congenic mice were obtained from Jackson Labs or NCI/Freder-
ick. TCRa-deficient mice were obtained from Taconic. Mice were maintained
in the NIAMS and NIAID animal facilities under animal-study protocols
approved by the appropriate NIH institute animal-care and -use committee.
Cell Preparation and Purification
Splenic DCs were sorted for high expression of CD11c+ on a MoFlo FACS
sorter (Dako Carpenteria, CA) from liberase-digested spleens. The purity of
CD11c+ DCs was at least 97%. T cells were purified from spleen and lymph-
node cell suspensions by magnetic depletion of non-T cells with FITC-conju-
gated mAb to CD11b, PanNK, B220, NK1.1, CD24, CD16/32, GR-1, and I-Ab
(BD pharmingen), followed by anti-FITC microbeads (Miltenyi). For purification
of CD4+ T cells, anti-CD8-FITC was added to the above antibodies. For naive
T cells, the CD62L+CD44 population of purified CD4+ cells was sorted after
staining with PE-Cy5 anti-CD44 and PE anti-CD62L. Bone-marrow-derived
DCs were generated by culture with RPMI/10% FCS supplemented with
10 ng/ml of murine GM-CSF (PeproTech, Rocky Hill, NJ). T cell-depleted an-
tigen-presenting cells were obtained by the incubation of spleen cell suspen-
sions with anti-Thy1.2 for 10 min on ice followed by incubation with low-tox-M
rabbit complement (Cedarlane laboratories) for 30 min at 37C. Cells were
washed and incubated with 25 mg/ml of mitomycin C (Sigma) for 30 min
at 37C.
T Cell Activation and Polarization
For costimulation studies, CD4+ or naive CD4+ cells were stimulated with
plate-bound anti-CD3 mAb (5 mg/ml or at the indicated concentration, 145-
2C11; BD PharMingen) in the presence or absence of plate-bound anti-
CD28 mAb (5 mg/ml) (37.51; BD PharMingen). Recombinant mouse TL1A
(R&D systems) was added at 10 ng/ml. For studies with Il2/ mice, purified
T cells were cultured as above but in the absence or presence of 10 U/ml of
IL-2. For DC-T cell coculture studies, 104 bone-marrow-derived DCs were cul-
tured with 105 OT-II or DR3-deficient OT-II naive CD4+T cells per well and the
indicated concentration of Ova323–339 peptide, with or without 10 mg/ml of
mouse CTLA4/Fc (Chimerigen). On day 3, culture supernatants were collected
for cytokine measurement, and cells were pulsed with 1 mCi of 3H-thymidine.
After an additional 16–20 hr, 3H-thymidine incorporation was measured with
a scintillation counter. For polarization studies, 8 3 105 T cell-depleted
APCs were cultured with 2 3 105 naive CD4+ T cells from C57BL/6 mice or
DR3-deficient mice. Th1 cell polarization was driven with rIL-12 (20 ng/ml) (Pe-
proTech, Rocky Hill, NJ) and anti-IL-4 (10 mg/ml); Th2 cell with rIL-4 (20 ng/ml)
(PeproTech, Rocky Hill, NJ), anti-IL-12 (10 mg/ml), and anti IFN-g (10 mg/ml);
Th17 cell with rhTGFb (5 ng/ml) (eBioscience), IL-6 (20 ng/ml) (eBioscience),
anti-IL-12 (10 mg/ml), anti IFN-g (10 mg/ml) and anti-IL-4 (10 mg/ml); and Th0
cell with anti-IL-12 (10 mg/ml), anti IFN-g (10 mg/ml) and anti-IL-4 (10 mg/ml).
After 4 days of culture, intracellular cytokine staining was performed as
described below. For polarization studies with STAg, 5 3 104 splenic DCs
were cultured with 105 OT-II or DR3-deficient OT-II naive CD4+T cells per
well with 1 mM of Ova323–339 peptide. Th1 cell polarization was driven with
rIL-12 (10 ng/ml), Th2 cell with rIL-4 (10 ng/ml), and STAg with 5 mg/ml of
STAg. After 72 hr of culture, supernatants were replaced with fresh medium
containing 10 U/ml of rIL-2, and after an additional 2–3 days, intracellular
cytokine staining was performed as described below.
Induction of Experimental Autoimmune Encephalomyelitis
Mice were immunized subcutaneously with myelin oligodendrocyte glycopro-
tein (MOG) 35-55 peptide in CFA, with pertussis toxin administrated intraper-
itoneally (i.p.) on days 0 and 2 to induce EAE. Five to eight mice were included
per group and were scored.
For transfer experiments in EAE, 23 107 CD4+ T cells fromC57BL/6 or DR3-
deficient mice were transferred into TCRa-deficient mice. Mice were immu-
nized with MOG peptide 24 hr after the transfer, and they were scored by clin-
ical assessment. Clinical assessment of EAEwas performed daily according to
the following criteria: (0), no disease; (1), tail paralysis; (2), hind-leg weakness;
(3), full hind-leg paralysis; (4), complete hind-limb paralysis plus front-limb
paraparesis; (5), death. Cells from the spinal cord were isolated with the use
of the Neural Tissue Dissociation Kit from Miltenyi Biotec according to theImmunity 29, 79–89, July 18, 2008 ª2008 Elsevier Inc. 87
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MOG-sensitized animals were isolated with CD4 beads. The cells were re-
stimulated in the presence of irradiated T cell-depleted splenocytes as APCs
and the indicated concentrations of MOG peptide in 96 well plates. On day
3, the cells were pulsed with 3H-thymidine for 6 hr and then harvested and
counted on a scintillation counter.
Ova-Induced Lung Hypersensitivity
On days 0 and 7, mice were sensitized systemically via a 200-ml i.p. injection
containing either 100 mg Chicken Ova (Sigma) or PBS emulsified in an equal-
volume mixture with alum (Pierce Laboratories, Rockford, IL). For assessment
of pulmonary inflammation, mice were challenged with 100 mg Ova or PBS/
30 ml inoculum, intratracheally (i.t.) on day 14 and intranasally (i.n.) on day
15. Mice were euthanized 48–72 hr after the final challenge for evaluation of
cell infiltration, cellular inflammation in the lung, and cytokine levels in the
sera and BAL fluid. For transfer experiments, OT-II or DR3-deficient OT-II
CD4 T cells were polarized under Th2 cell conditions for 5 days. The cells
were CFSE-labeled, and 2 3 106 cells were transferred into CD45.1 mice.
Mice were challenged with 100 mg Ova or PBS/30 ml inoculum administered
either i.t. after 24 hr and i.n. after 48 hr or i.t. after 48 hr. Mice were euthanized
24 hr after the final challenge for evaluation of cell infiltration, cellular inflamma-
tion in the lung, and cytokine levels in the sera and BAL fluid. BAL fluid was
obtained by direct cannulation of the lungs with a 20-gauge intravenous cath-
eter and lavage with 500 ml 1% fetal bovine serum (FBS) in PBS (for cytokine
analysis) and 750 ml 1% FBS in PBS (for analysis of cellular infiltration). Sam-
ples for cytokine analysis were stored at 80C. Samples for cellular analysis
were prepared as a cytospin (Thermo-Shandon, Pittsburgh, PA) for differential
cellular analysis after staining with Kwik-diff (Thermo-Shandon), and a portion
was used for determination of total cell counts. Lung histology was scored by
a reader, with experimental conditions masked as described previously
(McConchie et al., 2006). Inflammatory lung score was scored as follows: (0)
normal lung, minor inflammation, no goblet cells; (1) minor perivascular inflam-
mation (PVI)/cuffing (PVC); (2) moderate PVI and peribronchial inflammation
(PBI)/cuffing (PBC); (3) increased PVI and PBI, increased goblet cells, smaller
airways; (4) severe PVI and PBI, goblet cell infiltration of both small and large
airways (practically solid lungs).
Toxoplasma Infection
T. gondii cysts from theME-49 strain were prepared from the brains of infected
C57BL/6 mice. For experimental infections, mice were inoculated i.p. with an
average of 20 cysts/animal. At 7 weeks after infection, the number of cysts in
the brain of individual infected animals was determined. Spleen cells were har-
vested and cultured, then stimulated with either anti-CD3 and anti-CD28 or
5 mg/ml of STAg. Supernatants were harvested after 72 hr and analyzed for
cytokine production.
Trafficking of T Cells
53 106 CD4+ T cells fromDR3-deficient OT-II or OT-II control mice were trans-
ferred into CD45.1 congenic recipients, and the next daymicewere challenged
with 100 mg Ova protein and 5 mg LPS injected i.p. Three days later, lympho-
cytes were prepared from the indicated organs and analyzed by flow
cytometry.
Cytokine and Immunoglobulin Measurement
Detection of IFN-g-, IL-4-, and IL-17-producing cells was determined by intra-
cellular cytokine staining with anti IFN-g-APC, anti IL-4-PE, or anti-IL-17-PE
(BD Biosciences), respectively. In brief, cells were stimulated for 5 hr with
anti-CD3 and anti-CD28 or phorbol myristate acetate and ionomycin, with
monensin added after two hours. Cells were fixed in 3% paraformaldehyde,
permeabilized in 0.1% saponin, and analyzed on a FACS Calibur flow cytom-
eter (Becton Dickinson). Cytokine production in cell-culture supernatants was
analyzed by Cytometric Bead Array (BD Biosciences). Serum immunoglobu-
lins were measured by ELISA per the manufacturer’s instructions (Bethyl
Labs), and Ova-specific IgG1 and IgE were measured by IgG1- or IgE-specific
ELISA with plates coated with 50 ml of Ova (100 mg/ml).88 Immunity 29, 79–89, July 18, 2008 ª2008 Elsevier Inc.TL1A Induction in DCs and T Cells
Bone-marrow-derived DCs or splenic CD11c+ DCs from C57BL/6 mice and
the indicated knockout mice were cultured and stimulated for the indicated
time with or without 100 ng/ml of LPS, 20 mg/ml of SEA, or 10 mg/ml of
STAg. Stimulation with Ig crosslinking was performed by the coating of plates
with 0.5mg/ml of mouse IgG (Jackson Immunoresearch) for 1 hr at 37C, fol-
lowed by 50 mg/ml of sheep anti-mouse IgG (Jackson Immunoresearch) for
1 hr at 37C. Purified T cells were stimulated with 5 mg/ml of anti-CD3 and
anti-CD28 for the indicated time.
Measurement of RNA by Quantitative RT-PCR
Total RNA was isolated from cells with the use of TriZOL and the pure link
Micro-to-Midi Kit (Invitrogen). Quantitative RT-PCR was performed with the
use of an ABI PRISM 7700 sequence-detection system with SuperScript
One-Step RT-PCR System (Invitrogen). Predesigned primer/probe sets were
from Applied Biosystems, with the exception of TL1A, which was detected
with primers designed to recognize full-length TL1A (forward: 50-CCCCGGAA
AAGACTGTATGC-30; reverse: 50-GGTGAGTAAACTTGCTGTGGTGAA-30;
probe: 50-TCGGGCCATAACAGAAGAGAGATCTGAGC-30). Probes specific
for b2-microglobulin or CD3d were used as internal controls. Each measure-
ment of TL1Awas normalized to expression of b2-microglobulin or CD3d (delta
Ct), then measurements of stimulated and unstimulated were compared (delta
delta Ct). The inverse log of the delta-delta Ct was then calculated to give the
fold change. The level of TL1A in each sample was normalized to the TL1A level
of the same control cells.
SUPPLEMENTAL DATA
Supplemental data include five figures and can be found with this article online
at http://www.immunity.com/cgi/content/full/29/1/79/DC1/.
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